Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC
Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC
Active, not recruiting · NCT06059001 · Registry updated 2026-01-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 1 | 2026-01-14 | NCT06059001 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peptomyc S.L. | 3 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hospital Gregorio Marañon | Madrid | Spain | 4 |
| Hospital Miguel Servet | Zaragoza | Spain | 1 |
| Hospital Regional Universitario de Málaga | Málaga | Spain | 1 |
| Hospital Universitario Marqués de Valdecilla | Santander | Spain | 40 |
| Hospital Vall d´Hebrón | Barcelona | Spain | 1 |
| ICO Hopsitalet | L'Hospitalet de Llobregat | Spain | 1 |